Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
March 2017, Vol 10, Eighth Annual Payers' Guide
FDA Approvals
,
FDA Approvals
,
Drug Updates
,
Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2016
Read More
FDA Approvals
,
FDA Approvals
,
Drug Updates
,
Payers' Guide
Welcome to the Eighth Annual Payers’ Guide to New FDA Approvals
Read More
Select Drug Profiles
,
Payers' Guide
Darzalex (Daratumumab) Approved as Part of a 3-Drug Regimen for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Defitelio (Defibrotide Sodium): First Drug Approved for Patients with Hepatic Veno-Occlusive Disease
Laura Morgan
Read More
Select Drug Profiles
,
Payers' Guide
Gazyva (Obinutuzumab) Approved for Patients with Rituximab-Refractory Follicular Lymphoma
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Imbruvica (Ibrutinib) Now FDA Approved as First-Line Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes
Loretta Fala
Read More
1
2
Page 1 of 2
Results 1 - 10 of 14